key: cord-0948155-nc8n0otb
authors: Kanelidis, Anthony J.; Miller, Patrick J.; Singh, Amita; Addetia, Karima; Lang, Roberto M.
title: Takotsubo Syndrome from COVID-19 Infection
date: 2022-04-28
journal: J Am Soc Echocardiogr
DOI: 10.1016/j.echo.2022.04.011
sha: b1e8a9a376d678e67c982df7b46ad5f735805236
doc_id: 948155
cord_uid: nc8n0otb

nan

Takotsubo syndrome (TTS) or stress-induced cardiomyopathy is a rare form of acute, reversible, 3 left ventricular dysfunction. Catecholaminergic surge, myocardial inflammation, impaired 4 microvascular perfusion, and electrophysiological derangements may all contribute to its clinical 5 manifestations of myocardial stunning and apical ballooning. 1 6

The novel coronavirus disease (COVID-19) has been associated with various cardiovascular 7 manifestations, known as Acute COVID-19 Cardiovascular Syndrome (ACovCS), which include 8 but are not limited to acute coronary syndrome, myocarditis, microvascular disease, and TTS. 9

The pathophysiology of myocardial injury seen in COVID-19 is thought to be secondary to a 10 robust inflammatory response, including cytokine storm, which often is associated with elevated 11 inflammatory markers (e.g. D-dimer, ferritin, lactate dehydrogenase, C-reactive protein, and 12 erythrocyte sedimentation rate). 2, 3 We aim to explore the prevalence of TTS in COVID-19. 13

We conducted a retrospective study of consecutive patients with PCR confirmed COVID-19 who 14 had a TTE at a single academic center between April 2020 and March 2021. The TTE reports of 15 confirmed COVID-19 patients were queried for the terms "takotsubo", "stress", or "stress-16

induced cardiomyopathy" as well as for the presence of any regional wall motion abnormality 17 (i.e. "hypokinesis", "akinesis", or "dyskinesis"). These TTEs were reviewed by three 18 independent COCATS level III echocardiographers to confirm TTS based on the characteristic 19 presence of basal segment hyperkinesis with associated apical hypokinesis or "apical 20 ballooning", or atypical variants of TTS. Patients were excluded if they had preexisting 21 epicardial coronary artery disease or acute myocardial infarction by chart review. 22

During our study period there were a total of 1,308 patients admitted with COVID-19 infection, 2 of which 476 (36.4%) had TTEs during their index hospitalization. Our query resulted in 47 3

TTEs, of which nine met echocardiographic criteria for typical TTS. Four were excluded due to 4 the presence of CAD. The remaining five patients with COVID-19 and TTS had a mean age of 5 73 years, and three patients were female. The mean time from COVID-19 diagnosis to TTE was 6 1.6 days [1-3 days]. Laboratory test results revealed elevated inflammatory markers and elevated 7 cardiac biomarkers, in addition to the typical abnormalities seen on electrocardiogram (EKG) 8

and reduced left ventricular ejection fraction on TTE (Table 1) . TTE demonstrated the typical 9 "apical ballooning" pattern often seen in TTS ( Figure 1 ). We did not find any atypical variants of 10 TTS. The ischemic EKG findings improved over time in all patients and the three patients with 11

ST elevations had ST segments return to baseline an average of 13 days from the initial EKG. In 12 our cohort, the prevalence of typical TTS in patients with COVID-19 was 1%. how TTS may be appreciated more readily by reviewing TTEs with attention to typical wall 18 motion abnormalities seen in TTS. In our center alone, we found five patients with presumed 19 TTS compared to only 12 cases being previously published in the literature. We also had a high 20 percentage of hospitalized patients with COVID-19 get TTEs (36.4%), often due to elevated 21 high-sensitivity troponin T levels. To increase specificity, we excluded coexisting CAD, which 22 may confound the true prevalence of TTS. 23

While the pathophysiology of TTS is not fully understood, most TTS occurs in the setting of 2 severe emotional or medical/physical stress and is driven by excessive sympathetic nervous 3 system activation and a heightened catecholamine state. 5 Studies have shown that serum levels of 4 epinephrine and norepinephrine are higher in TTS, compared to patients undergoing myocardial 5 infarction, but this has not yet been studied in patients with COVID-19. 6 Furthermore, patients 6 with COVID-19 could also have some degree of microvascular dysfunction that predisposes 7 them to TTS. 7 COVID-19 is known to be associated with a severe inflammatory response, 8 including cytokine storm, which is manifested by high fevers and significantly elevated 9 inflammatory markersthis may be one possible mechanism for the development of TTS. 2 10 11 Our data suggest that patients with COVID-19 and elevated cardiac biomarkers as well as 12 Takotsubo  3 syndrome. Basal segment hyperkinesis and apical hypokinesis or "apical ballooning" can be seen 4 on contrast enhanced apical two-chamber views. 5 6 J o u r n a l P r e -p r o o f 

Pathophysiology of 2 Takotsubo Syndrome: JACC State-of-the-Art Review

What 4 We Know in 2021

Syndrome in 7 Patients with COVID-19: a Systematic Review of Published Cases

Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic 11 Criteria, and Pathophysiology

15 Reversible coronary microvascular dysfunction: a common pathogenetic mechanism in Apical 16 Ballooning or Tako-Tsubo Syndrome